Abstract
Advances in the drug treatment of inflammatory bowel disease include the development of site-specific delivery systems for 5-aminosalicylate (5-ASA), topically active corticosteroids with minimal systemic bioavailability, and a variety of antagonists to specific inflammatory mediators. These novel therapeutic approaches have emerged from pharmaceutical improvements on traditional drugs and also from an improved understanding of the mucosal immune system and the pathogenesis of inflammatory bowel disease.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Adjuvants, Immunologic / administration & dosage
-
Adrenal Cortex Hormones / administration & dosage
-
Aminosalicylic Acids / administration & dosage
-
Anti-Inflammatory Agents / administration & dosage*
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
-
Colitis, Ulcerative / drug therapy*
-
Crohn Disease / drug therapy*
-
Enema
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Mesalamine
-
Steroids
Substances
-
Adjuvants, Immunologic
-
Adrenal Cortex Hormones
-
Aminosalicylic Acids
-
Anti-Inflammatory Agents
-
Anti-Inflammatory Agents, Non-Steroidal
-
Immunosuppressive Agents
-
Steroids
-
Mesalamine